Announced
Completed
Financials
Tags
Venture Capital
Private
Private Equity
Cross Border
Completed
Acquisition
Biotechnology
biotechnology
Hong Kong
Minority
Friendly
Synopsis
Prosperity7, a boutique investment consulting firm, led a $35m Series D2 funding round in Insilico Medicine, a clinical-stage end-to-end artificial intelligence-driven drug discovery company, with participation from Aramco Ventures. "The deepening application of AI and machine learning for drug discovery has demonstrated a transformative positive impact on the pharmaceutical industry and we are delighted to embark on this partnership with Insilico Medicine, a frontrunner in this innovation. Backed by the breadth of Aramco’s ecosystem across geographies and sectors, we look to support the company to scale up and expand its footprint globally, to drive biotechnology excellence, and to bring positive impact for greater wellbeing," Aysar Tayeb, Prosperity7 Ventures Executive Managing Director.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.